Publications

  1. S.-G. Han, S. Ko, W.-K. Lee, S. T. Jung*, Y. G. Yu* (2017) “Determination of the endothelin-1 recognition sites of endothelin receptor type A by the directed-degeneration method”, Scientific Reports, Accepted.


  2. S. Chauhan, C. Y. Hou, S. T. Jung, T. J. Kang (2017) “Detection and Detection and purification of backbone-cyclized proteins using a bacterially expressed anti-myc-tag single chain antibody, Analytical Biochemistry, 532, 38-44.


  3. H. I. Park, H. W. Yoon, S. T. Jung*, (2016) “The highly evolvable antibody Fc domain", Trends in Biotechnology, 34:11, 895-908.


  4. M. Jo, S. T. Jung* (2016) “Engineering therapeutic antibodies targeting G-protein-coupled receptors”, Experimental and Molecular Medicine, 48, e207.


  5. M.-S. Ju, J.-H. Na, Y. G. Yu, J.-Y. Kim, C. Jeong, S. T. Jung* (2015) “Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding”, Molecular Immunology, 67, 350-356.


  6. S. H. Ko, S. T. Jung* (2015) “Engineering antibodies for dual specificity and enhanced potency”, Biotechnology and Bioprocess Engineering, 20, 201-210.


  7. S. T. Jung*, T. H. Kang, D. I. Kim (2014) “Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding”, Biotechnology and Bioprocess Engineering, 19, 780-789.


  8. M.-S. Ju, S. T. Jung*, (2014) “Aglycosylated full-length IgG antibodies steps toward next-generation immunotherapeutics, Current Opinion in Biotechnology, 30, 128-139.


  9. Laserson, U., F. Vigneault, D. Gadala-Maria, G. Yaari, M. Uduman, J. A. Vander Heiden, W. Kelton, S. T. Jung, Y. Liu, J. Laserson, R. Chari, J.-H. Lee, I. Bachelet, B. Hickey, E. Lieberman-Aiden, B. Hanczaruk, B. B. Simen, M. Egholm, D. Koller, G. Georgiou, S. H. Kleinstein, and G. M. Church, (2014) ” High-resolution antibody dynamics of vaccine-induced immune responses”, Proceedings of the National Academy of Sciences USA (PNAS), 111:13, 4928-4933


  10. S. T. Jung*, (2013) “Tailoring immunoglobulin Fc for highly potent and serum-stable therapeutic antibodies”, Biotechnology and Bioprocess Engineering, 18:4, 623-636.


  11. J.-H. Na, M.-S. Joo, W.-K. Lee, H. Shim, S.-H. Lim, S. T. Jung, Y. G. Yu, (2013) ”Development of a single chain antibody using a phage display cloning method for the detection of 2,4-dinitrotoluene”, Bulletin of Korean Chemical Society, 34:2, 460-464.


  12. H. H. Lee, S. T. Jung, (2013) ”Overexpression, crystallization, and preliminary X-ray crystallographic analysis of β-N-acetylglucosaminidase from Thermotoga maritime by the Tm0809 gene”, Acta Crystallographica Section F, 69:Pt2, 115-117.


  13. Y. Wine, D. R. Boutz, J. J. Lavinder, A. E. Miklos, R. A. Hughes, K. H. Hoi, S. T. Jung, A. P. Horton, A. D. Ellington, E. M. Marcotte, G. Georgiou, (2013) ”Molecular deconvolution of the polyclonal antibody serum response”, Proceedings of the National Academy of Sciences USA (PNAS), 110:8, 2993-2998.


  14. S. T. Jung, W. Kelton, T. H. Kang, D. T. Ng, J. T. Andersen, I. Sandlie, C. A. Sarkar, G. Georgiou, (2013) ”Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity”, ACS Chemical Biology, 8:2, 368-375.


  15. H. K. Yoon, S. T. Jung, J. Kim, T. H. Yoo, (2012) “Recent Development of Highly Sensitive Protease Assay Methods: Signal Amplification through Enzyme Cascades”, Biotechnology and Bioprocess Engineering, 17, 1113-1119.


  16. S. T. Jung*, (2012) “Engineering Aglycosylated Antibodies for Therapeutic Effector Functions and Production in Bacteria”, BT News, 19:2, 70-73.


  17. E. M. Brustad, V. S. Lelyveld, C. D. Snow, N. Crook, S. T. Jung, F. M. Martinez, T. J. Scholl, A. Jasanoff, F. H. Arnold, (2012) “Structure-guided directed evolution of highly selectively P450-based magnetic resonance imaging sensors for dopamine and serotonin”, Journal of Molecular Biology, 422:2, 245-262.


  18. M. J. Borrok, S. T. Jung, T. H. Kang, A. F. Monzingo, G. Georgiou, (2012) ”Revisiting the role of glycosylation in the structure of human IgG Fc”, ACS Chemical Biology, 7:9, 1596-1602.


  19. S. T. Jung, T. H. Kang, W. Kelton, G. Georgiou, (2011) “Bypassing glycosylation: Engineering aglycosylated full length IgG antibodies for human therapy, Current Opinion in Biotechnology, 22:6, 858-867.


  20. S. T. Jung, R. Lauchli, F. H. Arnold, (2011), “Cytochrome P450: taming a wild type enzyme”, Current Opinion in Biotechnology, 22:6, 809-817.


  21. J. Qiu, S. T. Jung, G. Georgiou, H. Hang, (2010), “Enrichment of Escherichia coli spheroplasts displaying scFv antibodies specific for antigens expressed on the human cell surface”, Applied Microbiology and Biotechnology, 88:6, 1385-1391.


  22. S. T. Jung, T. H. Kang, G. Georgiou (2010), “Efficient expression and purification of human aglycosylated Fcγ receptors in Escherichia coli”, Biotechnology and Bioengineering, 197:1, 21-30.


  23. S. T. Jung, S. T. Reddy, T. H. Kang, M. J. Borrok, I. Sandlie, P. W. Tucker, G. Georgiou (2010), “Aglycosylated IgG variants expressed in bacteria that selectively bind FcγRI potentiate tumor cell killing by monocyte-dendritic cells”, Proceedings of the National Academy of Sciences USA (PNAS), 107:2, 604-609.

    • Highlighted in Nature Biotechnology (2010), 28:1, 45, “Research Highlights”, “Receptor-selective aglycosylated Abs”,

    • Highlighted in Nature SciBX (Science Business eXchange) (2010), 3:3, Jan 21, 2010 issue, “Cover Story”, “mAbs that live long and prosper”,



    • http://www.nature.com/scibx/journal/v3/n3/full/scibx.2010.73.html  



  24. S. T. Jung, K. J. Jeong, B.L. Iverson, G. Georgiou (2007), “Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens”,  Biotechnology and Bioengineering, 98:1, 39-47.

    • Highlighted “Spotlight” Biotechnology and Bioengineering (2007), 98:1, “Toward the Isolation of Antibodies to Surface Biomarkes”.


  25. M. S. Kim, S. S. Kim, S. T. Jung, J. Y. Park, H. W. Yoo, J. Ko, K. Csizar, S. Y. Choi, and Y. Kim (2003), “Expression and purification of enzymatically active form of the human lysyl oxidase-like protein 4”, Journal of Biological Chemistry, 278:52, 52071-52074.


  26. S. T. Jung, M. S. Kim, J. Y. Seo, H. C. Kim, and Y. Kim (2003), “Purification of enzymatically active human lysyl oxidase and lysyl oxidase-like protein from Escherichia coli inclusion bodies”, Protein Expression and Purification, 31, 240-246.


  27. S. H. Kang, S. T. Jung, T. J. Kang, R. G. Kim, S. H. Suh, J. H. Woo, E. L. Lee, and C. Y. Choi (1999), “An efficient translational termination of human erythropoietin in Escherichia coli by altering the base following the stop codon”, Biotechnology and Techniques, 13, 761-764.


  28. T. J. Kang, S. H. Kang, S. T. Jung, E. L. Lee, and C. Y. Choi (1999), “A simple regression method for determining the quantity of translated protein in a cell free protein synthesis system”, Journal of Bioscience and Bioengineering, 88:3, 345-347.


Comments